FEDERAL TRADE COMMISSION v. ABBVIE INC et al

  1. August 03, 2015

    AbbVie Slams FTC's Bid To Review Pay-For-Delay Ruling

    A recent appellate court decision has no real bearing on the Federal Trade Commission's pay-for-delay case against AbbVie Inc. and other drugmakers, the companies told a Pennsylvania federal judge Friday, urging him to leave untouched a ruling that gutted the agency's case.

  2. July 21, 2015

    FTC Asks For Review Of AbbVie Pay-For-Delay Ruling

    The Federal Trade Commission on Monday formally asked a Pennsylvania federal judge to reconsider his decision to toss its pay-for-delay claims against AbbVie Inc. and Teva Pharmaceuticals USA Inc. over testosterone drug AndroGel, saying the ruling runs contrary to a new precedent issued by the Third Circuit.

  3. July 10, 2015

    FTC Gets Shot At Reviving AbbVie Pay-For-Delay Claims

    The Federal Trade Commission can file for reconsideration of a decision to toss its pay-for-delay claims against AbbVie Inc. and Teva Pharmaceuticals USA Inc. over testosterone drug AndroGel, a Pennsylvania federal judge has ruled, also allowing the agency to pause its bid for an immediate appeal.

  4. July 06, 2015

    AbbVie Says Reconsideration Not Needed In FTC Row

    AbbVie Inc. and others said Monday they don't believe a recent Third Circuit ruling provides any basis for a Pennsylvania federal judge to reconsider his decision dismissing part of the Federal Trade Commission's pay-for-delay lawsuit over testosterone drug AndroGel.

  5. July 02, 2015

    FTC Asks Court To Review AbbVie Pay-For-Delay Dismissal

    The Federal Trade Commission asked a Pennsylvania federal judge Wednesday to consider taking a second look at a May ruling that gutted the agency's pay-for-delay suit against AbbVie Inc. over testosterone drug AndroGel, following a recent Third Circuit decision in a similar case.

  6. June 26, 2015

    AbbVie Fights FTC's Quick Appeal Bid In Pay-For-Delay Case

    The Federal Trade Commission should be denied partial final judgment on a ruling that gutted a pay-for-delay suit against AbbVie Inc. over testosterone drug AndroGel, because the agency would not suffer any undue or incurable prejudice absent an immediate appeal, the defendants argued Thursday.

  7. June 22, 2015

    AbbVie Fights FTC Discovery Expansion In Pay-For-Delay Suit

    AbbVie Inc. wants to nix the U.S. Federal Trade Commission's bid for expanded discovery in the pay-for-delay suit over testosterone drug AndroGel, arguing in Pennsylvania federal court Friday that expansion will be unnecessary if the rest of the case is tossed.

  8. June 08, 2015

    FTC Asks For Quick Appeal Of AbbVie Pay-For-Delay Defeat

    The Federal Trade Commission asked a Pennsylvania federal judge Friday to enter partial final judgment on his May ruling that gutted the agency's pay-for-delay suit against AbbVie Inc. over testosterone drug AndroGel, a procedural move that would allow it to launch an immediate appeal.

  9. May 06, 2015

    Judge Trims FTC's Pay-For-Delay Suit Against AbbVie

    Teva Pharmaceuticals USA Inc. didn't violate federal antitrust law when it struck a deal with AbbVie Inc. and others to end patent infringement litigation, a Pennsylvania federal judge ruled Wednesday, dismissing part of the Federal Trade Commission's pay-for-delay lawsuit over testosterone drug AndroGel.

  10. April 30, 2015

    Discovery Tightened In FTC's AbbVie Pay-For-Delay Suit

    A Pennsylvania federal judge limited discovery Thursday to the sham litigation alleged in the first count of the Federal Trade Commission's suit against AbbVie Inc., which is accused of keeping Teva Pharmaceuticals USA Inc.'s generic AndroGel off the market.